{"paper_id":"8500d892-cc01-4775-9649-28dffbbc1b1f","body_text":"Abstract\nThe efficacy of danazol was assessed in 50 patients with myelofibrosis and anemia using the recently revised criteria of the International Working Group for Myelofibrosis Research and Treatment. According to them, anemia response (clinical improvement) is defined as transfusion cessation in transfusion-dependent patients or an Hb increase >2 g/dl in patients without transfusion requirements, both maintained for at least 12 weeks. Median follow-up from danazol start was 36 months (interquartile range [IQR] 19.2–58.8). Anemia response was achieved in 15 patients (30 %), including 5 of the 27 with transfusion dependency (18.5 %) and 10 of the 23 without transfusion requirements (43.5 %). Median time to response was 5 months (IQR 4–7) and median duration of the response 14 months (IQR 10–21). Among responder patients, 5 discontinued therapy due to toxicity or personal decision and 1 died from spleen rupture while being in response. A trend for worse response was seen in transfusion-dependent patients (p = 0.055). A platelet increase >50 × 109/l was observed in 3 of 13 thrombocytopenic patients, all of whom had moderate thrombocytopenia. Toxicity was usually moderate, leading to treatment withdrawal in only 4 patients. Danazol is effective in 30 % of patients with anemia-associated myelofibrosis. The responses are less frequent in patients with transfusion dependency.\nSimilar content being viewed by others\nReferences\nTefferi A (2000) Myelofibrosis with myeloid metaplasia. N Engl J Med 342:1255–1265\nCervantes F (2014) How I treat myelofibrosis. Blood 124:2635–2642\nTefferi A, Passamonti F, Barbui T, Barosi G, Begna K, Cazzola M, Cervantes F, Döhner K, Gisslinger H, Gupta V, Li W, Harrison CN, Kiladjian JJ, McMullin MF, Rambaldi A, Schiller GJ, Vannucchi AM, Mesa RA (2013) Phase 3 study of pomalidomide in myeloproliferative neoplasm (MPN)-associated myelofibrosis with RBC-transfusion dependence (abstract). Blood 122:394\nTefferi A, Cervantes F, Mesa R, Passamonti F, Verstovsek S, Vannucchi AM, Gotlib J, Dupriez B, Pardanani A, Harrison C, Hoffman R, Gisslinger H, Kroger N, Thiele J, Barbui T, Barosi G (2013) Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood 122:1395–1398\nCervantes F, Alvarez-Larrán A, Domingo A, Arellano-Rodrigo E, Montserrat E (2005) Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients. Br J Haematol 129:771–775\nTefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, Barosi G, Verstovsek S, Birgegard G, Mesa R, Reilly JT, Gisslinger H, Vannucchi AM, Cervantes F, Finazzi G, Hoffman R, Gilliland DG, Bloomfield CD, Vardiman JW (2007) Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 110:1092–1097\nBarosi G, Mesa RA, Thiele J, Cervantes F, Campbell PJ, Verstovsek S, Dupriez B, Levine RL, Passamonti F, Gotlib J, Reilly JT, Vannucchi AM, Hanson CA, Solberg LA, Orazi A, Tefferi A (2008) Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 22:438–439\nThiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A (2005) European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 90:1128–1132\nCervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, Vannucchi AM, Mesa RA, Demory JL, Barosi G, Rumi E, Tefferi A (2009) New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113:2895–2901\nPassamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, Guglielmelli P, Pungolino E, Caramella M, Maffioli M, Pascutto C, Lazzarino M, Cazzola M, Tefferi A (2010) A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 115:1703–1708\nReilly JT (1998) Pathogenesis and management of idiopathic myelofibrosis. Baillière’s Clin Hematol 11:751–767\nMartínez-Trillos A, Gaya A, Maffioli M, Arellano-Rodrigo E, Calvo X, Díaz-Beyá M, Cervantes F (2010) Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients. Ann Hematol 89:1233–1237\nHarrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoops L, Cervantes F, Vannucchi AM, Barbui T, Barosi G (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366:787–798\nCervantes F, Alvarez-Larrán A, Hernández-Boluda JC, Sureda A, Torrebadell M, Montserrat E (2004) Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. Br J Haematol 127:399–403\nCervantes F, Alvarez-Larrán A, Hernández-Boluda JC, Sureda A, Granell M, Vallansot R, Besses C, Montserrat E (2006) Darbepoetin-alpha for the anaemia of myelofibrosis with myeloid metaplasia. Br J Haematol 134:184–186\nTsiara SN, Chaidos A, Bourantas LJ, Kapsali HD, Bourantas KL (2007) Recombinant human erythropoietin for the treatment of anemia in patients with idiopathic myelofibrosis. Acta Haematol 11:156–161\nHuang J, Tefferi A (2009) Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level (letter). Eur J Haematol 83:154–155\nMesa RA, Steensma DP, Pardanani A, Li CY, Elliott M, Kaufmann SH, Wiseman G, Gray LA, Schroeder G, Reeder T, Zeldis JB, Tefferi A (2003) A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 101:2534–2541\nMesa RA, Yao X, Li CY, Litzow M, Paietta E, Rowe JM, Tefferi A, Tallman MS (2010) Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903. Blood 116:4436–4438\nQuintás-Cardama A, Kantarjian HM, Manshouri T, Thomas D, Cortes J, Ravandi F, Garcia-Manero G, Ferrajoli A, Bueso-Ramos C, Verstovsek S (2009) Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol 27:4760–4766\nTefferi A, Mesa RA, Nagomey DN, Schroeder G, Silverstein MN (2000) Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood 95:2226–2233\nHast R, Engstedt L, Jameson S, Killander A, Lundh B, Reizenstein P, Skarberg KO, Udén AM, Wadman B (1978) Oxymetholone treatment in myelofibrosis. Blut 37:19–26\nBrubaker LH, Brière J, Laszlo J, Kraut E, Landaw SA, Peterson P, Goldberg J, Donovan P (1982) Treatment of anemia in myeloproliferative disorders: a randomized study of fluoxymesterone v transfusions only. Arch Intern Med 142:1533–1537\nTefferi A, Verstovsek S, Barosi G, Passamonti F, Roboz GJ, Gisslinger H, Paquette RL, Cervantes F, Rivera CE, Deeg HJ, Thiele J, Kvasnicka HM, Vardiman JW, Zhang Y, Bekele BN, Mesa RA, Gale RP, Kantarjian HM (2009) Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol 27:4563–4569\nAcknowledgments\nThis work was supported in part by grant RD12/0036/0010 from the Instituto de Salud Carlos III, Spanish Ministry of Health.\nAuthorship contributions\nFrancisco Cervantes designed the research, interpreted the results, and wrote the manuscript. Ignacio M. Isola, Juan-Gonzalo Correa, Alberto Alvarez-Larrán, and Juan-Carlos Hernández-Boluda collected the data, revised the manuscript, and approved its final version. Arturo Pereira performed the statistical analysis, interpreted the results, and revised the manuscript.\nConflict of interest\nThe authors declare that they have no conflict of interest.\nAuthor information\nAuthors and Affiliations\nCorresponding author\nRights and permissions\nAbout this article\nCite this article\nCervantes, F., Isola, I.M., Alvarez-Larrán, A. et al. Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results. Ann Hematol 94, 1791–1796 (2015). https://doi.org/10.1007/s00277-015-2435-7\nReceived:\nAccepted:\nPublished:\nIssue date:\nDOI: https://doi.org/10.1007/s00277-015-2435-7","source_license":"CC0","license_restricted":false}